Skip to main content
Premium Trial:

Request an Annual Quote

Vanderbilt Medical Center to Use FDNA Technology for Disease Diagnosis

NEW YORK (GenomeWeb) – Vanderbilt University Medical Center has signed an agreement to integrate FDNA's Face2Gene next-generation phenotyping application suite into its workflow for evaluating difficult-to-diagnose patients, the company announced today.

Face2Gene uses facial analysis, deep learning, and artificial intelligence to evaluate symptoms of patients with rare genetic diseases and suggest possible diagnoses based on a database of more than 10,000 rare disease syndromes.

Under the terms of the deal, the Vanderbilt Center for Undiagnosed Diseases will use Face2Gene to assist in patient diagnosis in its role as a member of the National Institutes of Health's Undiagnosed Disease Network.

Additional terms were not disclosed.

FDNA has partnered with a number of groups recently to use its Face2Gene technology for disease diagnosis including PreventionGenetics, the Greenwood Genetic Center, GeneDx, and Blueprint Genetics.